Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsTXG -4.04%58 Earnings Yield (Joel Greenblatt) % is -0.36% as of Jun. 2026. GuruFocus rates TXG with a GF Score™ of 58/100 and a GF Value™ of $18.38 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 683 Healthcare Providers & Services companies, 10x Genomics ranks worse than 70.13% on this metric.
10x Genomics's Enterprise Value for the quarter that ended in Jun. 2026 was $4,521.8 Mil.
10x Genomics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-16.5 Mil. 10x Genomics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -0.36%.
The historical rank and industry rank for 10x Genomics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
TXG'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -29.6 Med: -2.98 Max: 1.73
Current: -0.24
During the past 9 years, the highest Earnings Yield (Joel Greenblatt) of 10x Genomics was 1.73%. The lowest was -29.60%. And the median was -2.98%.
TXG's Earnings Yield (Joel Greenblatt) % is ranked worse than 70.13% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 3.72
vs TXG: -0.24
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. 10x Genomics's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
10x Genomics Earnings Yield (Joel Greenblatt) % Related Terms
10x Genomics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
10x Genomicss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
10x Genomics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.5 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -0.36% mean?
10x Genomics (TXG) has a Earnings Yield (Joel Greenblatt) % of -0.36% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #479 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 70.1%.
Is 10x Genomics' Earnings Yield (Joel Greenblatt) % too high?
10x Genomics' current Earnings Yield (Joel Greenblatt) % is -0.36%. Based on the distribution chart, 10x Genomics ranks #479 out of 683 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, 10x Genomics has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Earnings Yield (Joel Greenblatt) % compare to HNGE and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #479 out of 683 companies for Earnings Yield (Joel Greenblatt) %. This places 10x Genomics in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.72, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Earnings Yield (Joel Greenblatt) % is -0.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.38, compared to a current price of $55.63 — trading 202.7% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -0.36%. 10x Genomics' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For 10x Genomics (TXG), the current Earnings Yield (Joel Greenblatt) % is -0.36% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $55.63 is trading 202.7% above its estimated GF Value™ of $18.38.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Earnings Yield (Joel Greenblatt) %: -0.36%
GF Value™: $18.38 vs. price of $55.63 (202.7% above fair value)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
58GF Score
Get the complete analysis for TXG
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
